A detailed history of Hm Payson & CO transactions in Pfizer Inc stock. As of the latest transaction made, Hm Payson & CO holds 634,130 shares of PFE stock, worth $17 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
634,130
Previous 658,910 3.76%
Holding current value
$17 Million
Previous $18.4 Million 0.46%
% of portfolio
0.32%
Previous 0.34%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$27.7 - $31.39 $686,406 - $777,844
-24,780 Reduced 3.76%
634,130 $18.4 Million
Q2 2024

Aug 13, 2024

BUY
$25.26 - $29.6 $508,711 - $596,114
20,139 Added 3.15%
658,910 $18.4 Million
Q1 2024

Jun 20, 2024

SELL
$25.89 - $29.73 $2.1 Million - $2.42 Million
-81,244 Reduced 11.28%
638,771 $17.7 Million
Q4 2023

Feb 13, 2024

SELL
$26.13 - $33.94 $2.52 Million - $3.28 Million
-96,625 Reduced 11.83%
720,015 $20.7 Million
Q3 2023

Nov 06, 2023

SELL
$32.09 - $37.51 $2.4 Million - $2.81 Million
-74,796 Reduced 8.39%
816,640 $27.1 Million
Q2 2023

Jul 17, 2023

SELL
$36.12 - $41.79 $27.8 Million - $32.2 Million
-769,617 Reduced 46.33%
891,436 $32.7 Million
Q1 2023

Apr 18, 2023

SELL
$39.39 - $51.28 $8.71 Million - $11.3 Million
-221,097 Reduced 11.75%
1,661,053 $67.8 Million
Q4 2022

Feb 06, 2023

BUY
$41.75 - $54.5 $1.61 Million - $2.1 Million
38,584 Added 2.09%
1,882,150 $96.5 Million
Q3 2022

Oct 25, 2022

BUY
$43.76 - $53.42 $1.06 Million - $1.29 Million
24,168 Added 1.33%
1,843,566 $80.7 Million
Q2 2022

Aug 15, 2022

BUY
$46.53 - $55.17 $3.7 Million - $4.39 Million
79,488 Added 4.57%
1,819,398 $95.4 Million
Q1 2022

May 12, 2022

BUY
$45.75 - $56.69 $2.92 Million - $3.62 Million
63,874 Added 3.81%
1,739,910 $90.1 Million
Q4 2021

Feb 15, 2022

BUY
$41.32 - $61.25 $1.65 Million - $2.45 Million
39,941 Added 2.44%
1,676,036 $99 Million
Q3 2021

Nov 30, 2021

BUY
$39.25 - $50.42 $268,705 - $345,175
6,846 Added 0.42%
1,636,095 $70.4 Million
Q2 2021

Aug 17, 2021

BUY
$35.91 - $40.68 $259,198 - $293,628
7,218 Added 0.44%
1,629,249 $63.8 Million
Q1 2021

Jun 15, 2021

SELL
$33.49 - $37.77 $591,533 - $667,131
-17,663 Reduced 1.08%
1,622,031 $58.8 Million
Q4 2020

Mar 10, 2021

BUY
$33.47 - $42.56 $262,404 - $333,670
7,840 Added 0.48%
1,639,694 $60.4 Million
Q3 2020

Dec 21, 2020

BUY
$31.75 - $37.25 $2.39 Million - $2.8 Million
75,287 Added 4.84%
1,631,854 $59.9 Million
Q2 2020

Aug 13, 2020

BUY
$30.12 - $36.54 $524,359 - $636,124
17,409 Added 1.13%
1,556,567 $50.9 Million
Q1 2020

Jul 01, 2020

SELL
$27.03 - $38.62 $2.53 Million - $3.62 Million
-93,686 Reduced 5.74%
1,539,158 $50.2 Million
Q4 2019

Feb 18, 2020

BUY
$32.92 - $37.36 $1.1 Million - $1.24 Million
33,295 Added 2.08%
1,632,844 $64 Million
Q3 2019

Nov 12, 2019

BUY
$32.49 - $42.13 $2.92 Million - $3.79 Million
89,926 Added 5.96%
1,599,549 $57.5 Million
Q2 2019

Aug 15, 2019

BUY
$36.98 - $41.52 $231,531 - $259,956
6,261 Added 0.42%
1,509,623 $65.4 Million
Q1 2019

Jul 31, 2019

BUY
$37.5 - $41.2 $55.7 Million - $61.2 Million
1,484,605 Added 7914.94%
1,503,362 $63.8 Million
Q4 2018

Feb 15, 2019

SELL
$38.47 - $43.86 $47.8 Million - $54.5 Million
-1,243,665 Reduced 98.51%
18,757 $819,000
Q3 2018

Nov 30, 2018

SELL
$34.47 - $41.81 $7.8 Million - $9.46 Million
-226,175 Reduced 15.19%
1,262,422 $55.6 Million
Q2 2018

Aug 27, 2018

BUY
$32.98 - $35.16 $73,347 - $78,195
2,224 Added 0.15%
1,488,597 $54 Million
Q1 2018

May 14, 2018

SELL
$31.91 - $37.02 $314,153 - $364,461
-9,845 Reduced 0.66%
1,486,373 $52.8 Million
Q4 2017

Feb 16, 2018

BUY
$33.26 - $35.29 $11,408 - $12,104
343 Added 0.02%
1,496,218 $54.2 Million
Q3 2017

Nov 06, 2017

BUY
$31.0 - $34.15 $46.4 Million - $51.1 Million
1,495,875
1,495,875 $53.4 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $150B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Hm Payson & CO Portfolio

Follow Hm Payson & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

News

Stay updated on Hm Payson & CO with notifications on news.